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Abstract
Development of a successful bioresponsive drug delivery system requires exquisite engineering of
materials so that they are able to respond to the signals stemming from the physiological
environment. In this study, we proposed a new Pluronic® based thermogelling system containing
matrix metalloproteinase-2 (MMP2) responsive peptide sequences. A novel thermosensitive
multiblock copolymer comprising an MMP2-labile octapeptide (Gly-Pro-Val-Gly-Leu-Ile-Gly-
Lys) was synthesized from Pluronic® triblock copolymer. The polymer was designed to form
thermogel at body temperature and degrade in presence of MMP overexpressed in the tumor. The
synthesized polymer was a multiblock copolymer with ~ 2.5 units of Pluronic®. The multiblock
copolymer solutions exhibited a reverse thermal gelation around body temperature. The gelation
temperatures of the multiblock copolymer solutions were lower than those of the corresponding
Pluronic® monomer at a particular concentration. The cytotoxicity of the synthesized polymer was
lower comparing to its monomer. The solubility of hydrophobic anticancer drug, paclitaxel, was
enhanced in the polymer solutions via micelle formation. The synthesized polymer was
preferentially degraded in presence of MMP. Paclitaxel release was dependent on the enzyme
concentration. These findings suggest that the synthesized polymer has the potential as controlled
drug delivery system due to its unique phase transition and bioresponsive behavior.
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The advance in technologies to engineer biomimetic materials has been an important
breakthrough that would greatly influence human health care [1–3]. Careful fabrication of
materials with precise consideration of the underlying cellular microenvironments made this
approach suitable for various biomedical applications. Biomimetic materials have been
consistently considered for drug delivery and tissue engineering [4–6]. These materials have
frequently been obtained by incorporating bioactive molecules such as proteins and peptides
[1, 7]. Particularly, peptide conjugation has been proven as a vital approach to develop the
biomimetic materials to suit the biomedical needs [8–10]. Several approaches have been
tried to engineer these materials either to target the diseased tissue or to mimic the
extracellular matrix [11–13].
Targeted delivery of anticancer drugs has been one of the pressing research areas using
bioactive molecules. Anticancer therapeutic agents, such as methotrexate, paclitaxel and
cisplatin, have been specifically delivered to tumor tissues by conjugating them to polymers
using bioactive molecules [14–18]. However, most polymeric prodrugs carrying pendent
cytotoxic drugs have been attached to polymer backbones via a peptide linker. The critical
problems associated with the polymeric prodrugs include low drug loading capacity and
altered physicochemical properties of the polymeric prodrug as a whole. Another drawback
associated with the polymeric prodrug is the release of peptide fragment-modified drug
rather than intact drug molecules, resulting in the reduced activity of parent drug [19]. An
alternative to overcome the problems associated with these approaches would be local drug
delivery systems with enhanced drug loading. Particularly, the local drug delivery systems
based on amphiphilic thermosensitive polymers has been investigated in recent years [20–
22]. The thermosensitive polymer solution is a free-flowing fluid at room temperature
allowing easy administration into the body. The polymer solution turns into gel depot upon
injecting into the body, where the gel depot acts a drug reservoir [23]. In addition, the
amphiphilic polymer can improve the solubility of insoluble drugs. From a clinical
perspective, the injectable thermogels have a great benefit because they allow minimally
invasive drug delivery directly to the diseased tissue.
Different thermogels were prepared with aqueous solutions of various polymeric materials
such as chitosan, hyaluronic acid, alginate, Pluronic® copolymers and poly(N-
isopropylacrylamide)-based copolymers [24–26]. Among the reported thermosensitive
polymers, Pluronic® copolymers, a class of polyethylene glycol-polypropylene glycol-
polyethylene glycol (PEG-PPG-PEG) triblock copolymers, were extensively studied due to
their drug loading capacity and acceptable biocompatibility [24, 27, 28]. It is worth
mentioning about an anticancer micellar formulation based on Pluronic® L61 and F127,
which has reached phase II clinical trials [29]. Besides the ability of the Pluronic®
copolymers to form micelles and thermogels, they are capable of sensitizing multi-drug
resistant cells and increasing drug transport across cellular barriers [30]. To overcome the
undesirable gel properties associated with Pluronic® triblock copolymers such as weak
mechanical strength and rapid erosion, multiblock copolymers made of PEG and PPG have
been proposed for enhanced physicochemical properties [31–35]. A family of disulfide
multiblock copolymers was synthesized from Pluronic® P65, P85 and P105 to prolong the
gel duration and to undergo thiol-dependent degradation [32]. Interestingly, the thermogels
of multiblock copolymers degraded and released paclitaxel in a glutathione-responsive
manner. Recently, PoligoGel®, a multiblock copolymer of PEG-PPG-PEG or PEG-
polybutylene glycol(PBG)-PEG connected via dicarboxylic linkages has been used for the
delivery of rat mesenchymal stem cells [33, 34]. The thermogel was shown to have potential
as a scaffold for the retention of cells at the target site. Novel thermogelling polymers based
on multiblock poly(ether ester urethane)s have been engineered from poly[(R)-3-
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hydroxybutyrate] (PHB), PEG and PPG using hexamethylene diisocyanate as a coupling
agent [35]. The thermogel showed improved gelation and drug release properties comparing
to Pluronic® triblock copolymers. Even though several different thermogelling systems have
been prepared, the drug release from the thermogels is mainly mediated by simple diffusion
and non-specific hydrogel erosion. These obstacles necessitate uncovering a specific
mechanism to control drug release from the thermogels. Matrix metalloprotenases (MMPs)
can act as in situ controlling tools to regulate drug release from the thermogels. MMPs are
zinc-dependent endopetidases that can cleave many of the extracellular matrix proteins.
Many of the MMPs are found to be overexpressed and active during advanced stages of the
cancer while they are minimally expressed in the normal tissue. Particularly, MMP2 and 9
(Type IV collagenases) which degrade extracellular matrices have been known to play a
critical role in tumor progression, angiogenesis and metastasis [8]. Therefore, the
combination of thermogelling property and enzyme sensitivity would provide a vital
approach to engineer novel in-situ forming polymers that are suitable for bioresponsive local
drug delivery.
A peptide specifically degraded by MMPs is either incorporated into or conjugated to a
thermosensitive polymer to make a thermogel system which is sensitive to MMPs. A
MMP13 sensitive peptide, QPQGLAK, has been incorporated into thermosensitive poly(N-
isopropyl acrylamide) hydrogel matrix [11, 12, 36]. The peptide in the hydrogel system
provided a cross-linking structure while maintaining thermosensitive properties. In addition,
the system showed concentration dependent degradation towards MMP2. Recently, an
enzymatically degradable temperature sensitive polypeptide has been reported. The block
copolymer, poly (ethylene glycol)-block-poly (alanine-co-phenyl alanine) (PEG-PAF),
showed temperature sensitivity in water as well as degradability in the subcutaneous layer of
rats [9]. Enzymes present in the subcutaneous layer such as cathepsin B, cathepsin C and
elastase were assumed to be responsible for the degradation of polymer in vivo.
Here we report the synthesis of novel Pluronic®-based multiblock copolymer connected via
a MMP-2-sensitive peptide, Gly-Pro-Val-Gly-Leu-Ile-Gly-Lys-NH2 (GPVGLIGK-NH2).
The hypothesis behind this project is that the combination of thermosensitive Pluronic® and
MMP-sensitive peptide would result in a dual-stimuli-sensitive polymer which can form gel
at body temperature and allow bioresponsive degradation in presence of MMP. Physical
properties and in vitro cytotoxicity of the polymers were studied to assess in vivo
applicability as a local drug delivery system. Finally, a chemotherapeutic agent, Paclitaxel




The peptide, GPVGLIGK-NH2, was synthesized by American Peptide Company (Vista,
CA). Pluronic® P85 and P104 were kindly provided from BASF Chemical Company
(Florham Park, NJ). Collagenase-IV was purchased from Sigma (Saint Louis, MO). PTX
was obtained from LC Laboratories (Woburn, MA). Polystyrene standards of molecular
weights 1, 4, 20, 50 and 100K were purchased from Polysciences, Inc. (Warrington, PA).
All other chemicals were obtained from Fisher Scientific (Pittsburgh, PA) and used without
further purification.
2.2. Polymer synthesis
2.2.1. Activation of triblock copolymer—Pluronic® P85 or P104 (10 g) was dried by
azeotropic distillation from 150 mL of anhydrous toluene. The dried Pluronic® was
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dissolved in 20 mL of anhydrous methylene chloride. About 2 mL of triethylamine (9.6
molar equiv.) was added to the reaction mixture at room temperature. After cooling the
reaction mixture in an ice bath, 4-nitrophenyl chloroformate (NPC) (8.0 molar equiv.) was
added. Initially, the mixture was allowed to react for 1 h at 0°C. The reaction was continued
overnight at room temperature under magnetic stirring. After all the solvent was removed,
the activated Pluronic® (NPC-Pluronic®) was dissolved in 50 mL of anhydrous ethyl acetate
and filtered to remove precipitated triethylamine HCl. The NPC-Pluronic® was
reprecipitated from 50 mL of diethyl ether to remove unreacted NPC. This step was repeated
twice to remove most of the unreacted NPC. Finally, the NPC-Pluronic® was dried under
reduced pressure and kept in a desiccator until peptide coupling.
2.2.2. Coupling of the peptide to activated triblock copolymer—The peptide (100
mg) and NPC-Pluronic® (1.1 molar amount to the peptide) were dissolved separately in 1
mL of dimethyl acetamide (DMA). NPC- Pluronic® solution was added to the peptide
solution at room temperature by magnetic stirring. Triethylamine (5.0 molar amount to the
peptide) was slowly added to the reaction mixture. The reaction was carried out for one day
(at room temperature) or two days (first day at room temperature and second day at 50°C) or
three days (one day at room temperature and two days at 50°C). Dry nitrogen was flushed to
evaporate DMA from the reaction mixture. This crude multiblock copolymer was dissolved
in water and dialyzed (molecular weight cut off: 6000–8000, Spectra/Por®) against
deionized water for two days with periodic media changes. The final product was freeze-
dried to obtain polymer powder. Two different multiblock copolymers, MMP-P85 from
Pluronic® P85 and MMP-P104 from Pluronic® P104, were synthesized with the yields of
80% and 89%, respectively.
2.3. Polymer characterization
1H-nuclear magnetic resonance (1H-NMR) was used to analyze the chemical structures of
the synthesized polymers. Polymers were dissolved in either CDCl3 or D2O and the spectra
were recorded on a 400MHz NMR spectrometer (Bruker Ultrashield™ 400 PLUS,
Germany). Waters gel permeation chromatography (GPC) system (Waters, Milford, MA)
equipped with a binary pump (Waters 1525), a refractive index detector (Waters 2414) and a
Styragel HR4E column (300 × 7.8 mm I.D., 5 µm particle size) was used to obtain the
molecular weights and polydispersities of the polymers. Tetrahydrofuran was eluted at a
flow rate of 1 mL/min at 25°C. Polystyrene standards (1000–50000 Da) were also run to
obtain a calibration curve and the calibration curve was used to calculate the molecular
weights of the polymers. Thermograms of the polymers were obtained from differential
scanning calorimeter (DSC) (Perkin Elmer Diamond DSC, Waltham, MA). Melting
temperatures of the polymers were determined from the thermograms thereafter. DSC was
run in the temperature range of 0 to 50°C with a heating and cooling rate of 10°C/min.
Initially, the samples were loaded in aluminum pans and equilibrated at 0°C for 5 min. Dry
nitrogen flow at a rate of 20 mL/min was maintained throughout the analysis.
2.4. Critical micelle concentration (CMC) of MMP-P104
The CMCs of Pluronic® P104 and MMP-P104 were determined by a dye solubilization
method using 1,6-diphenyl-1,3,5-hexatriene (DPH) [27]. Briefly, polymer solutions in the
concentration range 1.0 × 10−5 to 10 wt% were prepared. DPH solution (10 µL, 0.4 mM in
methanol) was added to 1.0 mL of each polymer solution. The polymer solutions were
incubated at 25°C for 24 h in a dark place. The absorbance values of the test solutions were
recorded on a Lambda EZ201 UV spectrophotometer (Perkin Elmer, Waltham, MA) at 377
and 391 nm. A graph was drawn plotting the difference between two absorbance values on
vertical axis and concentration on horizontal axis.
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2.5. DSC of polymer solutions
DSC thermographs of Pluronic® P104 and MMP-P104 solutions were obtained in the
concentration range of 1 to 25 wt%. Sample solutions were prepared by dissolving specific
amount of polymer in deionized water with gentle stirring at 4°C. Accurately weighed
sample solutions (6 mg) were placed in aluminum cells and reference cells were made up
with same amount of deionized water. DSC was run in the temperature range of −10 to 50°C
at a rate of 5°C/min. Samples were thermally equilibrated at −10°C for 15 min before the
scanning.
2.6. Circular dichroism (CD) spectroscopy
The CD spectra of MMP-P104 and peptide solutions were analyzed in the wavelength range
of 250 to 190 nm using a CD spectrometer (Olis® DSM 20 CD Spectrophotometer, Bogart,
GA). MMP-P104 and peptide solutions were prepared at 0.1 and 0.01 wt%, respectively.
The sample solutions were equilibrated at 4°C overnight before the analysis. A cuvette (path
length-1mm) was charged with a sample solution and CD spectra were recorded at 15, 25,
35 and 45°C. Molar ellipticity of all the samples was calculated after a blank reference of
water was subtracted from the raw data.
2.7. In vitro cytotoxicity
In vitro cytotoxicity study was performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) on HT1080 fibrosarcoma cells [37]. The cells were cultured in
Roswell Park Memorial Institute medium (RPMI). The RPMI was supplemented with 10%
fetal bovine serum (FBS) and antibiotics. The cultured cells in 96-well plates (5 × 103 cells/
well) were grown for 24 h at 37°C. The culture medium was replaced with MMP-P104
solution (100 µL, 0.05–1.00 wt %) in serum-free Dulbecco’s Modified Eagle’s Medium
(DMEM). The cells were incubated for 4 h in serum-free DMEM (100 µL) followed by 12 h
incubation in 200 µL DMEM containing 10% FBS. After 16 h of total incubation, the test
solutions were replaced with fresh media (200 µL) and 5 mg/mL MTT solution (20 µL). The
cells were incubated for 4 h in MTT solution. Later, the MTT solution was replaced with
400 µL dimethyl sulfoxide to dissolve internalized purple formazan crystals. To measure the
absorbance at 570 nm on a VICTOR3 V™ Multilabel Counter (Perkin Elmer, MA, USA),
150 µL of the solution was transferred from each well into a fresh 96-well plate. Cell
viability was calculated as compared to phosphate buffered saline (PBS)-treated cells (100
% survival).
2.8. Thermal gelation of polymeric solutions
2.8.1. Test tube inverting method—Polymer solutions were prepared by dissolving
them in deionized water at 4°C. A series of polymer solutions at concentrations of 5, 10, 15,
20 and 25 wt% were prepared. Scintillation vials (4mL) were loaded with 1mL of the
polymer solution and incubated at 4°C overnight. The sol-gel and gel-sol phase transition
temperatures of the each polymer solution were determined with increments of 2°C [24, 38].
The experiment was conducted in the temperature range of 15 to 80°C. The temperature at
which a polymer solution stopped flowing upon a tube inversion was recorded as gelation
temperature.
2.8.2. Falling ball method—MMP-P104 solutions at concentrations of 10, 15, 20 and 25
wt% were prepared in deinonized water. NMR tube of diameter 4.0 mm was filled with the
polymer solution. The polymer solution was incubated at 10°C for 20 min. A steel ball
(diameter (D) =1.97 mm, density (ρs) = 7.97 g/mL) was dropped through the polymer
solution. The time (t) required for the steel ball to fall a specified distance (d = 3 cm) was
measured with a temperature increment of 2°C per step for each polymer concentration. The
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polymer solutions were equilibrated for 20 min at each temperature. The intersection of
extrapolated lines of travel time of the steel ball on a graph plotted between temperature and
the transit time gives the sol-gel transition temperature of the polymer solution [39]. The
dynamic viscosity (μ) was calculated using the following formula
Where, the velocity of the falling ball (ν) = d/t, specific gravity of the sphere (γs) = ρsg,
specific gravity of the polymer solution (γf) = ρfg, and acceleration due to gravity (g) = 980
cm/s2. The density of the polymer solution (ρf) was assumed to be 1.0 g/cm3.
2.9. MMP-P104 degradation
The MMP-P104 solution was prepared at a concentration of 25 wt% in deinonized water.
The polymer solution (50 µL) was placed in 1mL vials and the vials were kept at 4°C
overnight. The polymer solutions were incubated at 37°C for 15 min for gelation. Phosphate
buffer (0.1mL, 50mM) was added to first three vials (control). In another three vials,
phosphate buffer containing collagenase-IV (250µg/mL) was added. The degradation of the
gels was stopped by freezing the gels at predetermined time intervals. The frozen samples
were then freeze-dried to get the degraded polymer. GPC was run to check the molecular
weight distribution of the degraded polymer.
2.10. In vitro paclitaxel release
MMP-P104 (250mg) was dissolved in 200µL of the acetone. After partial removal of
acetone by dry nitrogen flushing, 20µL of the acetone containing 500µg of PTX was added
to the polymer solution. By continuously mixing the polymer-drug mixture, the acetone was
removed by dry nitrogen flushing. Finally, the polymer-drug mixture was vacuum dried in
vacuum for 4 h to remove the acetone completely. The MMP-P104-PTX mixture was
dissolved in 750 µL water with vigorous stirring at 4°C. The polymer-drug solution (0.2
mL) was placed in each 2 mL vial and allowed for gelation at 37°C. The gels were
equilibrated at this temperature for 15 min. Phosphate buffer (1.6mL, 50mM) including 1%
w/v Tween 80 was added to first set of vials (control). Phosphate buffer (1.6mL, 50mM)
composed of collagenase-IV (1, 10, 50 and 250µg/mL), Tween 80 (1% w/v), calcium
chloride (0.5mM) and sodium azide (0.2mg/mL) was added to another set of vials. While
incubating at 37°C, samples were collected and total medium was replaced for every 12 h to
maintain perfect sink conditions. The samples were analyzed for PTX by high performance
liquid chromatography (HPLC). Waters HPLC system (Waters, Milford, MA) was equipped
with a binary pump, dual absorbance detector, and XTerra® RP 18, 5 µm column (4.6 × 150
mm). A mixture of acetonitrile and water in the ratio of 55:45 was eluted at a flow rate of 1
mL/min at 25°C and the detection wavelength was set to 230 nm.
3. RESULTS & DISCUSSION
Multiblock copolymers (MMP-P85 and MMP-P104) were synthesized by conjugating
thermosensitive Pluronic® (P85 and P104), a group of triblock copolymer of PEG-PPG-
PEG, to a MMP-sensitive peptide (GPVGLIGK-NH2). The synthesis involves a two-step
reaction as described in Scheme 1. The 1H-NMR spectra of Pluronic® P104 and purified
NPC-Pluronic® were shown in Figure 1. The activation of Pluronic® was confirmed by the
characteristic proton peaks of 4-nitrophenyl carbonate ranging from 7.4 to 8.4 ppm in 1H-
NMR spectrum [40]. Figure 1A shows the proton peak of hydroxyl protons (c) at each end
of the Pluronic®. The hydroxyl proton peak was disappeared in the NMR spectrum (Figure
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1B) upon the activation of Pluronic®. In addition, the appearance of proton peak of the
methylene group (f) at 4.45ppm confirmed the successful activation of the Pluronic®.
Several peptide sequences such as GPLGIAGQ, GPQGPAGQ, PVGLIG, and CGLDD have
shown MMP susceptibility [13, 14, 19]. An octapeptide sequence (GPVGLIGK-NH2) has
been synthesized to conjugate to the Pluronic® moiety. An MMP-sensitive hexapeptide
(PVGLIG) [19] was modified at the ends with two amino acids (glycine and lysine) to
provide amine functional groups on both ends. The modification in the peptide would allow
the conjugation reaction to the terminals while maintaining MMP-sensitive cleavage of the
peptide at –GL– [41]. The terminal amino groups of the peptide allowed the linear
oligomerization between the peptide and NPC- Pluronic®. As Pluronic® of molecular
weight ~ 5000 may not be easily accessible for the oligomerizaion, the reaction time and
temperature were increased to check the effect of these parameters on the final molecular
weight of MMP-P104. Table 1 summarizes the molecular weights of MMP-P104 at different
reaction conditions. The molecular weight of MMP-P104 slightly increased on increasing
the reaction time and temperature. Figure 1-C shows the 1H-NMR spectrum of MMP-P104.
The oligomerization was confirmed by the characteristic proton peaks of peptide and
Pluronic® in the final polymer. The proton peaks at g to ν shows the presence of peptide and
its conjugation to Pluronic®.
Determined molecular characteristics of Pluronic® copolymers, MMP-P85 and MMP-P104
were summarized in Table 2. The calculated molecular weights of MMP-P85 and MMP-
P104 were found to be 15290 and 23540 g/mol respectively. The molecular weight analysis
indicates that MMP-P85 and MMP-P104 are multiblock copolymers with 2.06 and 2.76
units of Pluronic® P85 and Pluronic® P104 respectively. Comparing to previously reported
Pluronic®-based multiblock copolymers [24], multiblock copolymers with relatively low
molecular weights were achieved because of relatively high molecular weight peptide (~740
g/mol) which might limit the access of the nitro group at the end of the Pluronic® to the
amine group in the peptide during oligomerization. According to DSC data, the melting
temperatures (Tm) of MMP-P85 and MMP-P104 were found to be 28.5 (±1.8) and 30.9
(±2.2) °C. The Tm values of multiblock copolymers are lowered comparing to the Tm values
of Pluronic® monomers. This lowering of the Tm values of MMP-P85 and MMP-P104 may
be due to the interrupted polymer packing by the incorporation of a peptide in the polymer
structure [24].
The relatively high molecular weight of MMP-P104 made this multiblock copolymer an
interested candidate comparing to MMP-P85. So, the further characterization was mainly
performed with MMP-P104. A hydrophobic dye (DPH) solubilization method was used to
measure the CMC of MMP-P104 [24, 27]. The absorbance of DPH has sharply increased at
CMC of the MMP-P104 (Figure 2). The CMC was calculated by extrapolating the
absorbance versus logarithmic concentration. The CMC of MMP-P104 was found to be
0.208 (±0.012) wt% which is slightly lower than the CMC of Pluronic® P104 (0.300
(±0.009) wt%). This lowering of the CMC is mainly attributed to the increased molecular
weight of MMP-P104. This can be explained in two ways. First, at a given PPO/PEO ratio,
higher molecular weight Pluronic® polymers form micelles more readily than the lower
molecular weight polymers [42]. Second, the easy micelle formation is favored for
multiblock copolymer as covalently bonded PPGs facilitate easy hydrophobic core
formation during micelle structuring [27].
The polymer solutions were further characterized for critical micellization temperature
(CMT). The micellization process is characterized by endothermic peak during the heating
cycle in DSC. The onset temperature at which micelles start to form is considered as the
CMT at the particular polymer concentration. Figure 3 shows the comparison between CMT
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values of Pluronic® P104 and MMP-P104 solutions at different concentrations. The trend in
CMT changes with polymer concentration was in accordance with phase transition of
Pluronic® P104 [42, 43]. The CMT of MMP-P104 slightly lowered than that of Pluronic®
P104 at each polymer concentration. This is mainly due to the higher molecular weight of
the multiblock copolymer comparing to Pluronic® P104. High molecular weight block
polymers are known to be more favorable for micelle formation than low molecular weight
polymers [42].
Secondary structures of MMP-P104 and peptide in solution were analyzed using CD
spectroscopy as a function of temperature. Formation of α- helices (one positive band
centered at ~ 195 nm and two negative bands between 205–225 nm) or β- sheets (one
positive band centered at ~ 195 nm and one negative band between 210–220 nm) or random
coils (one negative band centered at ~ 195 nm and one positive band centered at ~ 215 nm)
will show characteristic CD spectra [8]. Spectra of both peptide and MMP-P104 suggested
the random coil arrangement of MMP-sensitive peptide in the multiblock copolymer in an
aqueous environment. Pluronic® did not show a considerable effect on the random coil
arrangement of peptide in water. Figure 4 shows the CD spectra of MMP-P104 at 15, 25, 35
and 45°C. As the temperature of polymer solutions increased, no visible change in the CD
spectra was observed. Also, the effect of temperature on the random coil arrangement of
peptide is very minimum (supporting information: Figure S4) indicating that the temperature
does not affect the secondary structural arrangement of the octapeptide in MMP-P104.
Cytotoxicity of Pluronic® P104 and MMP-P104 was assessed by MTT assay using HT1080
fibrosarcoma cells. As HT1080 cells are known to express different types of MMPs,
especially MMP 2 and 9, they were chosen for the assessment of the cytotoxicity [44, 45].
Figure 5 shows the results of MTT assay in the polymer concentration ranging from 0.05 to
1.00 wt%. It is shown that MMP-P104 resulted in a greater cell viability comparing to
monomeric Pluronic® P104. The difference in cytotoxicity can be attributed to molecular
weight difference between MMP-P104 and Pluronic® P104. Previously, a Pluronic® P104
based multiblock copolymer (MBCP 2) of molecular weight ~ 40000 showed cell viability
of >80% [24]. Therefore the increase in polymer molecular weight would be a vital means to
improve the biocompatibility of MMP-P104. Biocompatible MMP-104 with increased
molecular weight would provide an ideal cancer drug delivery platform which can achieve
bioresponsive drug release as well as enhanced cytotoxicity to cancer cells with the
sensitizing effect from released Pluronic® P104.
The fundamental properties such as sol-gel and gel-sol transition temperatures of Pluronic®
P104 and MMP-P104 polymer solutions were evaluated by test tube inverting method and
falling ball method. Figure 6 shows the phase diagram of MMP-P104 and Pluronic® P104 at
different polymer concentrations. The sol-gel transition temperatures determined by test tube
inverting method are in good agreement with the values determined by falling ball method.
Due to an extended equilibration time during the execution of falling ball method, a slight
difference in gelation temperature was observed between two methods. At all polymer
concentrations tested for gelation, MMP-P104 solutions were free flowing liquids at room
temperature which could be easily injected through 25-guage needle. Upon increasing the
temperature to 37°C, the solution immediately turned into gel depending on the polymer
concentration. Figure 7 shows the change in viscosities with temperature of MMP-P104
solutions at different polymer concentrations. The viscosities are below 500 g/cm.sec−1
during the “sol” state where as they ranged between 1000–9000 g/cm.sec−1 during the “gel”
phase for all the measured concentrations. MMP-P104 solutions showed sol-gel-sol
transition in the range of 10–25 wt%. But, the Pluronic® P104 (25wt%) solution showed sol-
gel-sol-gel-sol transition on increasing the temperature. Formation of isotropic or cubic
crystalline phases is responsible for gelation at low temperature whereas formation of multi-
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phases (cubic/hexagonal/lamellar) cause gelation at high temperature [46]. The sol-gel
transition temperatures of MMP-P104 were lowered comparing to Pluronic® P104 at
particular concentration. For example, at 25 wt% the gelation temperature of Pluronic®
P104 was 68.5°C whereas the gelation temperature of MMP-P104 was 30.7°C. In addition
to the sol-gel transition, the critical gelation concentration (CGC) of MMP-P104 was also
lowered comparing to the CGC of Pluronic® P104. The alteration in the gelation properties
was mainly attributed to the increase in the micelle size due to increased molecular weight
of MMP-P104 comparing to Pluronic® P104 (supporting information: Table S2). Therefore,
the larger micelle size resulting from multiblock copolymer might be the reason for lower
CGC with facile and/or extensive polymer interactions comparing to Pluronic® P104
micelles.
Figure 8 shows the GPC chromatographs of degraded MMP-P104 in presence or absence of
MMP. An MMP concentration of 250µg/mL was chosen to study the polymer degradation
in a facilitated condition. MMP-P104 degraded rapidly in presence of MMP showing
complete polymer degradation within 24 h while the polymer degraded much slower in the
absence of MMP. Complete polymer degradation was observed at the end of day 12 without
the enzyme. GPC was also run on Pluronic® P104 to compare the changes in
chromatographs. The chromatograph of completely degraded MMP-P104 was similar to that
of Pluronic® P104 indicating that the multiblock copolymer degraded into its monomeric
units. Considering the MMP-cleavable site in the peptide, the possible degradation products
of multiblock copolymer would be the Pluronic® monomers with four amino acids on both
the terminals. However, remaining peptide segments will be eventually degraded into amino
acids by proteases in the body.
MMP-P104 solutions demonstrated quick gelation which occurred within a minute below
body temperature at a polymer concentration of 25 wt%. Based on this observation, 25 wt%
was selected for in vitro PTX release. The achieved PTX concentration in 25 wt% MMP-
P104 solution was found to be 0.847 (±0.019) mg/mL. The achieved PTX concentration was
nearly 200-fold increase in PTX solubility in water with a PTX concentration increase from
0.004 mg/mL to 0.847 mg/mL in the presence of the polymer. PTX release from the MMP-
sensitive thermogel was investigated at four different MMP concentrations as well as in
MMP free media. Release profiles have been summarized in Figure 9. PTX release lasted
for 2, 5 and 8 days at MMP concentrations of 50, 10, and 1 µg/mL, respectively. Rapid drug
release due to the erosion of the gels was observed in presence of MMP. Based on the
consistency between PTX release and polymer degradation, it is notable that erosion played
a main role in the drug release in presence of MMP. On the other hand, both erosion and
diffusion have caused sustained drug release up to 13 days in the absence of MMP.
Precise drug release from an in-situ formed hydrogel depot to achieve a local therapeutic
drug concentration is a difficult task since there is no viable mechanism to control drug
release once it forms a depot. The hydrogel depot is expected to monotonously release
incorporated drug at a predetermined rate until incorporated drug is completely exhausted.
The presence of an extra mechanism that is able to control drug release even beyond in-situ
depot formation and secure a therapeutic level of drug will be highly desirable for successful
local drug delivery particularly for detrimental diseases such as cancers. MMP-sensitive
thermogels were tested for cooperative drug release by diffusion and enzymatic hydrogel
degradation which may be useful for the achievement of effective local drug delivery
potentially for cancers. The thermogel was challenged with an alternating medium change to
simulate an MMP-elevation in cancer. As shown in Figure 10, the thermogel immediately
increased PTX release upon a medium replacement from MMP-free medium to MMP-
containing medium. Upon an addition of MMP at a concentration of 250µg/mL, cumulative
PTX release was dramatically increased from 27% to complete drug release within 24 hr.
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The MMP-sensitive PTX release demonstrated in Figures 9 and 10 is completely in
accordance with the polymer degradation presented in Figure 8. Marked increase in drug
release from the MMP-sensitive thermogel suggests the capability of MMP-sensitive
thermogel as a bioresponsive local drug delivery platform which would be particularly
applicable for cancer drug delivery.
4. CONCLUSIONS
MMP-sensitive thermogelling polymers have been successfully synthesized for potential
drug delivery applications by incorporating an MMP-sensitive peptide into an amphiphilic
multiblock copolymer. The aqueous solution of the synthesized polymer underwent gelation
at body temperature. In addition, the gelation temperature of the polymer solutions varied
depending on the polymer concentration. The cytotoxicity of the synthesized polymer was
lower comparing to the corresponding monomer. The secondary structure of the peptide
inside the thermogel was confirmed to be a random coil arrangement. The polymer was
rapidly degraded in presence of MMP. The synthesized polymer greatly enhanced the
solubility of a hydrophobic cancer drug, paclitaxel. The polymer gels exhibited the release
of incorporated drug in a bioresponsive manner.
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1H-NMR spectra of (A) Pluronic® P104, (B) Activated Pluronic® P104 and (C) MMP-P104.
CDCl3 was used to measure the NMR spectra of all polymers.
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CMC determination of MMP-P104 using a dye solubilization method. The CMC is defined
as the point of intersection of two exponential lines. The CMC of MMP-P104 was found to
be 0.208 (±0.012) wt%. The CMC value represents the mean ±SD of three experiments.
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Determination of CMT values of Pluronic® P104 and MMP-P104 solutions by DSC. The
CMT value represents the mean ±SD of three experiments.
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CD spectra of MMP-P104 at different temperatures. Molar ellipticity was plotted on the
vertical axis. All the solutions showed a negative band at ~ 195 nm and a positive band at
~215 nm.
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Cell viability as a function of concentration was measured for Pluronic® P104 and MMP-
P104 on HT1080 cells. The results represent the mean ±SD for n=3.
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Phase diagrams of Pluronic® P104 and MMP-P104 aqueous solutions constructed by both
test tube inverting method and falling ball methods. The results represent mean ±SD for
n=3.
Garripelli et al. Page 18














Dynamic viscosity measurement of MMP-P104 solutions as a function of temperature.
Dynamic viscosity was measured using falling ball method for different polymer
concentrations.
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GPC chromatographs showing MMP-P104 polymer degradation in presence or absence of
MMP. The multiblock copolymers were degraded into lower molecular weight monomers.
At 0 h, a small amount of unreacted Pluronic® P104 was detected in the chromatographs of
MMP-P104.
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PTX release at different MMP concentrations such as 0, 1, 10 and 50 µg/mL. The results
represent mean ±SD for n=3.
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PTX release from MMP-P104 thermogels with an alterating challenge of MMP free medium
following MMP containing medium. The addition of MMP in the release medium at a
concentration of 250 µg/mL triggered a fast drug release. The results represent mean ±SD
for n=3.
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Two step reaction scheme showing the synthesis of MMP-sensitive multiblock copolymers
from Pluronic® (P85 or P104) triblock copolymers. Pluronic® and NPC were reacted at
room temperature for overnight to activate Pluronic®.
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Table 1
Effect of different reaction conditions on the molecular weight of the final polymer. The Mn values represent
mean ± SD for n=3.
Polymer Reaction conditions Mn (g/mol)a Mw/Mnb
1 RT (one day) 17570 (± 1060) 1.34
2 RT (one day) + 50°C (one day) 21120 (± 960) 1.47
3 RT (one day) + 50°C (two days) 23270 (± 1100) 1.33
a
Number average molecular weights determined by GPC
b
Polydispersities based on GPC measurements
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Table 2
Characterization of multiblock copolymers and triblock monomers. The Mnand Tm values represent mean ±
SD for n=3.
Polymer Mn(g/mol)a Mw/Mnb Number ofrepeating units
Tm (°C)c
Pluronic® P85 7410 (± 120) (4600d) 1.06 - 38.9 (± 1.2)
Pluronic® P104 8520 (± 110) (5900e) 1.05 - 39.4 (± 0.9)
MMP-P85 15290 (± 920) 1.47 2.06 28.5 (± 1.8)
MMP-P104 23540 (± 1100) 1.33 2.76 30.9 (± 2.2)
a
Number average molecular weights determined by GPC
b
Polydispersities based on GPC measurements
c
Melting temperatures determined by DSC
d,e
Molecular weights from BASF chemical company
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